Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Maio

Showing results (11-20 of 250) with videos related to

Pageof 25
Sort By:
Vaccines|September 8, 2015
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyGiorgio Parmiani, Cristina Maccalli, Michele Maio
The Lancet. Oncology|February 3, 2022
Nivolumab plus ipilimumab in melanoma brain metastasesAnna Maria Di Giacomo, Michele Maio
Cardiovascular Research|February 2, 2006
Is it the primetime for endoglin (CD105) in the clinical setting?Michele Maio, Maresa Altomonte, Ester Fonsatti
Journal of Cellular Physiology|May 16, 2002
Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001Giovan Giacomo Giordano, Luca Sigalotti, Michele Maio
Tumori|June 21, 2008
The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European levelMichele Maio, Ester Fonsatti, Arianna Burigo, et al.
Seminars in Oncology|November 16, 2010
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indicationsLuana Calabrò, Riccardo Danielli, Luca Sigalotti, et al.
Seminars in Oncology|November 16, 2010
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indicationsAnna Maria Di Giacomo, Maurizio Biagioli, Michele Maio
Seminars in Oncology|May 13, 2015
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapiesAlexander M M Eggermont, Michele Maio, Caroline Robert
Journal of Translational Medicine|June 29, 2004
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?Ester Fonsatti, Anna Maria Di Giacomo, Michele Maio
Pharmacology & Therapeutics|January 4, 2014
Epigenetic drugs as immunomodulators for combination therapies in solid tumorsLuca Sigalotti, Elisabetta Fratta, Sandra Coral, et al.
Pageof 25

Showing results (11-20 of 250) with videos related to

Sort By:
Pageof 25
Vaccines|September 8, 2015
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyGiorgio Parmiani, Cristina Maccalli, Michele Maio
The Lancet. Oncology|February 3, 2022
Nivolumab plus ipilimumab in melanoma brain metastasesAnna Maria Di Giacomo, Michele Maio
Cardiovascular Research|February 2, 2006
Is it the primetime for endoglin (CD105) in the clinical setting?Michele Maio, Maresa Altomonte, Ester Fonsatti
Journal of Cellular Physiology|May 16, 2002
Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001Giovan Giacomo Giordano, Luca Sigalotti, Michele Maio
Tumori|June 21, 2008
The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European levelMichele Maio, Ester Fonsatti, Arianna Burigo, et al.
Seminars in Oncology|November 16, 2010
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indicationsLuana Calabrò, Riccardo Danielli, Luca Sigalotti, et al.
Seminars in Oncology|November 16, 2010
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indicationsAnna Maria Di Giacomo, Maurizio Biagioli, Michele Maio
Seminars in Oncology|May 13, 2015
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapiesAlexander M M Eggermont, Michele Maio, Caroline Robert
Journal of Translational Medicine|June 29, 2004
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?Ester Fonsatti, Anna Maria Di Giacomo, Michele Maio
Pharmacology & Therapeutics|January 4, 2014
Epigenetic drugs as immunomodulators for combination therapies in solid tumorsLuca Sigalotti, Elisabetta Fratta, Sandra Coral, et al.
Pageof 25